What's Happening?
Novartis has announced its acquisition of Myricx Bio, a UK-based startup specializing in antibody-drug conjugate (ADC) technology, for up to $1.5 billion. Myricx Bio, a spin-out from Imperial College London and the Francis Crick Institute, has developed
a novel payload class targeting cancer cells, which is delivered by a targeting antibody. This acquisition includes an upfront payment of $1.1 billion and potential milestone payments of $400 million. Myricx's technology focuses on n-myristoyltransferase inhibitor (NMTi) payloads, which target enzymes crucial for cancer cell survival. The company claims its candidates can regress tumors resistant to current payloads, offering a differentiated toxicity profile. Novartis aims to leverage its R&D resources to establish this technology as a new class of ADCs, potentially broadening their use across various tumor settings.
Why It's Important?
The acquisition of Myricx Bio by Novartis is significant as it represents a strategic move to enhance Novartis' oncology portfolio with innovative ADC technology. ADCs are crucial in cancer treatment, but resistance to existing payloads limits their effectiveness. Myricx's NMTi payloads offer a promising alternative, potentially overcoming resistance and expanding treatment options for patients. This deal underscores the importance of developing new mechanisms to improve cancer therapies and highlights Novartis' commitment to advancing biomedical research. The acquisition could accelerate the development and availability of new cancer treatments, benefiting patients with resistant or unresponsive tumors.
What's Next?
The transaction is expected to close by the end of the year, with Novartis planning to advance Myricx's lead candidates targeting B7-H3 and HER2 into human trials. These antigens are well-validated in cancer research, and the trials could provide critical data on the efficacy of Myricx's NMTi payloads. Novartis' involvement may expedite the development process, potentially bringing these new treatments to market faster. The acquisition is part of Novartis' broader strategy to expand its oncology pipeline, following other recent acquisitions aimed at enhancing its drug portfolio.
